Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded Revision: v3.4.2; removed the funding-lapse notice and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check22 days agoChange DetectedAdded a government funding notice about NIH operations and updated the site revision to v3.4.1, replacing v3.4.0.SummaryDifference0.1%

- Check29 days agoChange DetectedGlossary toggle is now visible; metadata labels have standardized capitalization (No FEAR Act Data). The revision tag has been updated from v3.3.4 to v3.4.0.SummaryDifference0.1%

- Check65 days agoChange DetectedExpanded the study site locations with a broader set of recruitment sites across the United States and worldwide, and removed several previously listed locations.SummaryDifference4%

- Check87 days agoChange DetectedFooter revision label updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check94 days agoChange DetectedAdded notes clarifying that publications can be entered voluntarily and may be auto-filled from PubMed; a revision label v3.3.1 was added, replacing the former v3.2.0 wording.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.